Literature DB >> 21317831

PharmGKB summary: methotrexate pathway.

Torben S Mikkelsen1, Caroline F Thorn, Jun J Yang, Cornelia M Ulrich, Deborah French, Gianluigi Zaza, Henry M Dunnenberger, Sharon Marsh, Howard L McLeod, Kathy Giacomini, Mara L Becker, Roger Gaedigk, James Steven Leeder, Leo Kager, Mary V Relling, William Evans, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21317831      PMCID： PMC3139712          DOI： 10.1097/FPC.0b013e328343dd93

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  124 in total

1.  High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

Authors:  Thomas Rau; Birgit Erney; Ralf Göres; Thomas Eschenhagen; Jörn Beck; Thorsten Langer
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

2.  Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.

Authors:  Judith A M Wessels; Wouter M Kooloos; Robert De Jonge; Jeska K De Vries-Bouwstra; Cornelia F Allaart; Annelies Linssen; Gerard Collee; Peter De Sonnaville; Jan Lindemans; Tom W J Huizinga; Henk-Jan Guchelaar
Journal:  Arthritis Rheum       Date:  2006-09

Review 3.  Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice.

Authors:  Gary D Kruh; Martin G Belinsky; James M Gallo; Kun Lee
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

4.  Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.

Authors:  Hiroyuki Imanishi; Noboru Okamura; Mariko Yagi; Yukari Noro; Yuka Moriya; Tsutomu Nakamura; Akira Hayakawa; Yasuhiro Takeshima; Toshiyuki Sakaeda; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-12-19       Impact factor: 3.172

5.  Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.

Authors:  Kim Robien; Jeannette Bigler; Yutaka Yasui; John D Potter; Paul Martin; Rainer Storb; Cornelia M Ulrich
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

6.  Ancestry and pharmacogenetics of antileukemic drug toxicity.

Authors:  Shinji Kishi; Cheng Cheng; Deborah French; Deqing Pei; Soma Das; Edwin H Cook; Nobuko Hijiya; Carmelo Rizzari; Gary L Rosner; Tony Frudakis; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

7.  Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.

Authors:  Azza A K El-Sheikh; Jeroen J M W van den Heuvel; Jan B Koenderink; Frans G M Russel
Journal:  J Pharmacol Exp Ther       Date:  2006-09-27       Impact factor: 4.030

8.  Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.

Authors:  Andong Qiu; Michaela Jansen; Antoinette Sakaris; Sang Hee Min; Shrikanta Chattopadhyay; Eugenia Tsai; Claudio Sandoval; Rongbao Zhao; Myles H Akabas; I David Goldman
Journal:  Cell       Date:  2006-12-01       Impact factor: 41.582

9.  Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.

Authors:  R J H M van der Straaten; Judith A M Wessels; Jeska K de Vries-Bouwstra; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Judith Bogaartz; Marco Tiller; Tom W J Huizinga; Henk-Jan Guchelaar
Journal:  Pharmacogenomics       Date:  2007-02       Impact factor: 2.533

10.  Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.

Authors:  Donato Gemmati; Alessia Ongaro; Silvia Tognazzo; Linda Catozzi; Federica Federici; Endri Mauro; Matteo Della Porta; Diana Campioni; Antonella Bardi; Giuseppe Gilli; Agnese Pellati; Angelo Caruso; Gian L Scapoli; Monica De Mattei
Journal:  Haematologica       Date:  2007-04       Impact factor: 9.941
View more
  38 in total

Review 1.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

2.  Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.

Authors:  Courtney S Watts; Joseph N Sciasci; Jennifer L Pauley; John C Panetta; Deqing Pei; Cheng Cheng; Caroline M Christensen; Torben S Mikkelsen; Ching-Hon Pui; Sima Jeha; Mary V Relling
Journal:  J Pediatr Hematol Oncol       Date:  2016-08       Impact factor: 1.289

Review 3.  From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource.

Authors:  Ellen M McDonagh; Michelle Whirl-Carrillo; Yael Garten; Russ B Altman; Teri E Klein
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

4.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

5.  An LC-MS chemical derivatization method for the measurement of five different one-carbon states of cellular tetrahydrofolate.

Authors:  Li Chen; Gregory S Ducker; Wenyun Lu; Xin Teng; Joshua D Rabinowitz
Journal:  Anal Bioanal Chem       Date:  2017-08-10       Impact factor: 4.142

6.  Mathematical modeling of folate metabolism.

Authors:  John C Panetta; Steven W Paugh; William E Evans
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-05-22

7.  Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Authors:  R Franca; P Rebora; N Bertorello; F Fagioli; V Conter; A Biondi; A Colombini; C Micalizzi; M Zecca; R Parasole; F Petruzziello; G Basso; M C Putti; F Locatelli; P d'Adamo; M G Valsecchi; G Decorti; M Rabusin
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

8.  Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.

Authors:  Morten Tulstrup; Takaya Moriyama; Chuang Jiang; Marie Grosjean; Jacob Nersting; Jonas Abrahamsson; Kathrine Grell; Lisa Lyngsie Hjalgrim; Ólafur Gísli Jónsson; Jukka Kanerva; Bendik Lund; Stine Nygaard Nielsen; Rikke Linnemann Nielsen; Ulrik Overgaard; Petter Quist-Paulsen; Kaie Pruunsild; Goda Vaitkeviciene; Benjamin Ole Wolthers; Hui Zhang; Ramneek Gupta; Jun J Yang; Kjeld Schmiegelow
Journal:  Blood       Date:  2020-09-03       Impact factor: 22.113

9.  5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.

Authors:  Serena Pastore; Gabriele Stocco; Valentina Moressa; Luigi Zandonà; Diego Favretto; Noelia Malusà; Giuliana Decorti; Loredana Lepore; Alessandro Ventura
Journal:  Rheumatol Int       Date:  2014-09-21       Impact factor: 2.631

Review 10.  Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2016-07-05       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.